Key result
Inhibition of STAT3 or LPL in chronic lymphocytic leukemia cells decreased their capacity to oxidize free fatty acids and reduced cell viability.
Population
Chronic lymphocytic leukemia (CLL) cells, normal B cells, and MM1 cells
Design
Preclinical
Authors
Loading...
STAT3-LPL inhibition impairs CLL metabolism in models; leaves open whether this axis is a viable therapeutic target in patients.
STAT3 induces LPL expression in CLL cells, enabling them to oxidize free fatty acids, suggesting STAT3 inhibition could target CLL cell metabolism.
Rozovski et al. (2015) studied Chronic lymphocytic leukemia (CLL). STAT3 and LPL inhibition (STAT3-shRNA, LPL-siRNAs) was evaluated on LPL expression, free fatty acid oxidation capacity, and cell viability. Inhibition of STAT3 or LPL in chronic lymphocytic leukemia cells decreased their capacity to oxidize free fatty acids and reduced cell viability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: